FDA approves Cobenfy, a new treatment for schizophrenia
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.
Drugs
Health
Pharma
Drugs
Health
Pharma
Bristol Myers to acquire Karuna Therapeutics for $14 billion
HQ Team December 23, 2023: Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio,.
Drugs
Health
Pharma
KarXT by Karuna Therapeutics offers hope for improved schizophrenia management
HQ Team, December 18, 2023: For individuals grappling with schizophrenia, the road to treatment is often marked by a lifelong commitment to antipsychotic.